5125292026-10-015125292026-10-012026-10-01iso4217:INRxbrli:pure512529VIYASH SCIENTIFIC LIMITEDVIYASHNOTLISTEDINE807F01027Updatefalse2026-10-0116:11:002026-06-082026-09-082026-10-01Acquisition (including agreement to acquire)Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we hereby inform you that, Alivira Animal Health Limited, Ireland, step-down wholly owned subsidiary of the Company, has entered into a binding agreement today i.e. June 8, 2026, for the acquisition of 100% shareholding of BioForLife Italia s.r.l., Milan, Italy. The aggregate consideration for the transaction is EUR 16.975 million, structured as follows: a. EUR 15.0 million payable at closing; and b. EUR 1.975 million as deferred consideration, in accordance with the terms of the transaction documents. The transaction is subject to fulfilment of the applicable conditions precedent and receipt of such statutory and regulatory approvals as are applicable to the transaction.Transaction Completed19341000002026-10-011The transaction has been completed in accordance with the terms of the SPA and the connected transaction documents. The base purchase consideration being paid on the closing is comprising of EUR 15.0 million and the agreed reference net financial position computed as of June 30th 2026 in terms of the SPA. The balance purchase consideration of EUR 1.976 million is payable as deferred consideration, subject to necessary adjustments basis the computation of net financial position as on Closing Date (i.e October 1, 2026), in accordance with the SPA. As part of closing under the SPA, the representatives of Alivira Ireland have been appointed on the Board of BFL Italy.Deferred consideration payable at future date has been translated at today’s exchange rate. RBI reference rate of 01 October 2026 has been considered for Amount of Transaction Completed (Rs. in Crore) disclosed as above.